Leerink Partnrs Analysts Raise Earnings Estimates for SPRY

ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) – Equities researchers at Leerink Partnrs increased their Q2 2025 EPS estimates for ARS Pharmaceuticals in a research report issued to clients and investors on Sunday, June 22nd. Leerink Partnrs analyst R. Ruiz now anticipates that the company will post earnings per share of ($0.42) for the quarter, up from their prior estimate of ($0.43). The consensus estimate for ARS Pharmaceuticals’ current full-year earnings is ($0.55) per share. Leerink Partnrs also issued estimates for ARS Pharmaceuticals’ Q4 2025 earnings at ($0.27) EPS, FY2026 earnings at ($0.60) EPS, FY2027 earnings at $0.56 EPS and FY2028 earnings at $2.67 EPS.

SPRY has been the topic of a number of other reports. Wall Street Zen lowered ARS Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Thursday, May 22nd. William Blair restated an “outperform” rating on shares of ARS Pharmaceuticals in a research report on Monday, March 3rd. Finally, Scotiabank assumed coverage on shares of ARS Pharmaceuticals in a research note on Friday, March 7th. They issued a “sector outperform” rating and a $30.00 target price on the stock. One research analyst has rated the stock with a sell rating, five have given a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat, ARS Pharmaceuticals has a consensus rating of “Moderate Buy” and a consensus price target of $31.00.

ARS Pharmaceuticals Trading Up 2.9%

Shares of SPRY stock opened at $17.26 on Wednesday. The company has a market capitalization of $1.70 billion, a PE ratio of -107.87 and a beta of 0.84. ARS Pharmaceuticals has a 52-week low of $7.66 and a 52-week high of $18.51. The business’s fifty day moving average is $14.50 and its 200 day moving average is $12.95. The company has a debt-to-equity ratio of 0.30, a quick ratio of 10.74 and a current ratio of 11.00.

ARS Pharmaceuticals (NASDAQ:SPRY) last announced its quarterly earnings results on Wednesday, May 14th. The company reported ($0.35) EPS for the quarter, meeting the consensus estimate of ($0.35). The firm had revenue of $7.97 million during the quarter, compared to the consensus estimate of $7.48 million. ARS Pharmaceuticals had a negative net margin of 16.11% and a negative return on equity of 6.94%.

Insiders Place Their Bets

In other ARS Pharmaceuticals news, Director Laura Shawver sold 50,002 shares of the business’s stock in a transaction on Monday, April 7th. The shares were sold at an average price of $12.30, for a total value of $615,024.60. Following the completion of the sale, the director now directly owns 210,346 shares of the company’s stock, valued at $2,587,255.80. The trade was a 19.21% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Also, insider Alexander A. Fitzpatrick sold 102,969 shares of the firm’s stock in a transaction dated Tuesday, May 20th. The shares were sold at an average price of $14.10, for a total value of $1,451,862.90. Following the transaction, the insider now directly owns 89,613 shares in the company, valued at $1,263,543.30. This trade represents a 53.47% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 337,971 shares of company stock valued at $4,721,888 over the last 90 days. Insiders own 33.50% of the company’s stock.

Institutional Investors Weigh In On ARS Pharmaceuticals

A number of hedge funds and other institutional investors have recently modified their holdings of SPRY. Bernard Wealth Management Corp. bought a new position in ARS Pharmaceuticals during the 4th quarter worth approximately $27,000. ANTIPODES PARTNERS Ltd purchased a new stake in shares of ARS Pharmaceuticals during the first quarter valued at approximately $37,000. PNC Financial Services Group Inc. boosted its stake in shares of ARS Pharmaceuticals by 78,100.0% during the first quarter. PNC Financial Services Group Inc. now owns 3,910 shares of the company’s stock valued at $49,000 after purchasing an additional 3,905 shares during the period. KLP Kapitalforvaltning AS bought a new position in shares of ARS Pharmaceuticals in the fourth quarter worth approximately $73,000. Finally, BNP Paribas Financial Markets purchased a new position in shares of ARS Pharmaceuticals in the fourth quarter worth $75,000. Institutional investors own 68.16% of the company’s stock.

ARS Pharmaceuticals Company Profile

ARS Pharmaceuticals, Inc, a biopharmaceutical company, develops treatments for severe allergic reactions. The company is developing neffy, a needle-free and low-dose intranasal epinephrine nasal spray for the emergency treatment of Type I allergic reactions, including anaphylaxis. It serves healthcare professionals, patients, and caregivers.